WBIO — Wockhardt Bio AG Share Price
Last trade - 00:00- CH₣1.04m
- -CH₣154.18m
- $297.12m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.33 | ||
| Price to Tang. Book | 0.42 | ||
| Price to Free Cashflow | 2.26 | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 336.15 | 337.03 | 315.14 | 264.94 | 297.12 | n/a | n/a | -2.14% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | -58.61 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Wockhardt Bio AG is a Germany-based pharmaceutical company. It is active in the development, manufacturing and marketing of pharmaceutical and biopharmaceutical formulations. It offers a portfolio of generic drugs, which includes approximately 600 pharmaceuticals in various dosages and forms. Its offering covers several therapeutic categories, such as central nervous system agents, hormones, cardiovascular agents, anti-infective and respiratory agents, as well as gastrointestinal, dermatological and biological agents. The Company supplies markets in the United States, the United Kingdom, Ireland, France and Latin America. Additionally, it exports its pharmaceutical products to over 50 countries.
Directors
- Last Annual
- March 31st, 2022
- Last Interim
- March 31st, 2017
- Incorporated
- October 17th, 2005
- Public Since
- December 19th, 2013
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Berne eXchange
- Shares in Issue
- 51,948,000
- Address
- Grafenauweg 6, ZUG, 6300
- Web
- http://www.wockhardtbio.com/
- Phone
- +41 417275220
- Auditors
- BDO LTD
Upcoming Events for WBIO
FAQ
As of Today at 19:25 UTC, shares in Wockhardt Bio AG are trading at CH₣1.54. This share price information is delayed by 15 minutes.
Shares in Wockhardt Bio AG last closed at CH₣1.54 and the price had moved by -8.33% over the past 365 days. In terms of relative price strength the Wockhardt Bio AG share price has underperformed the FTSE Global All Cap Index by -16% over the past year.
There is no consensus recommendation for this security.
Find out moreWockhardt Bio AG does not currently pay a dividend.
Wockhardt Bio AG does not currently pay a dividend.
Wockhardt Bio AG does not currently pay a dividend.
To buy shares in Wockhardt Bio AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CH₣1.54, shares in Wockhardt Bio AG had a market capitalisation of CH₣80.00m.
Here are the trading details for Wockhardt Bio AG:
- Country of listing: Switzerland
- Exchange: BRN
- Ticker Symbol: WBIO
Based on an overall assessment of its quality, value and momentum Wockhardt Bio AG is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Wockhardt Bio AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -6.23%.
As of the last closing price of CH₣1.54, shares in Wockhardt Bio AG were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Wockhardt Bio AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CH₣1.54.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Wockhardt Bio AG's management team is headed by:
- Shekhar Datta - CHM
- Ajay Sahni - MDR
- Ravindra Limaye - DRC